Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

y Rat Neurons by a GABA-Independent Pathway in presentation P-192. About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the United States Food and Drug Administration, European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our Web Site at: www.neurochem.com.

This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that ac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... N.J. , July 30, 2015  Medimetriks ... completed the second Phase III clinical study for ... for impetigo.  Medimetriks owns the exclusive U.S. rights ... global trial, conducted at 44 centers with an ... pediatric patients aged 2 months and older with ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... , , Part ... SPRING, Md., Nov. 19 The U.S. Food and ... called the International Internet Week of Action (IIWA), intended ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s ...
... NEWS, Va., Nov. 19 Breast-Specific Gamma Imaging/Molecular Breast ... highly esteemed organizations for the fight against breast cancer: ... College of Surgeons. Both societies published articles supporting the ... early detection of breast cancer. , "These endorsements reinforce ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3
(Date:7/30/2015)... ... 2015 , ... The Mesothelioma Applied Research Foundation (Meso Foundation) ... of 2015’. The bill was introduced in Congress yesterday by Representatives John Katko ... Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill is ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of ... prison system, which has amassed largely enough throughout the years. Florida is the third ... Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning to ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back ... 26, 2015 from 10:00 AM to 2:00 PM local time. On the 26th, ...
(Date:7/30/2015)... ... , ... Bird B Gone, the leader in bird control products for commercial, ... pest birds from the AC units and ventilation systems on hospital roofs. Bird droppings ... West Nile virus. When these droppings dry, the fine powder can be carried into ...
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry eye season, ... that a particularly long, dry and hot 2015 summer season and the dry eye ... advocate Sharon Kleyne will discuss the 2015 summer season and identify the primary dry ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... the nation,s leading,supplier of replacement medical repair parts for ... companies in Ohio by the Case Western,Weatherhead School of ... growth rate exceeding 1000% and has won the award ... clearly one of our region,s most prestigious,honors," said PartsSource ...
... could yield targeted treatments for leukemia, bone marrow transplants ... of all human blood cells has been identified by ... to new treatments for blood cancers and other blood ... progenitor, is the initial offspring of a blood-forming stem ...
... Inc.,(NYSE: BMR ) today announced that its board ... $0.31 per share of common stock. The,dividend is equivalent ... BioMed also announced that its board of directors ... company,s 7.375% Series A Cumulative,Redeemable Preferred Stock for the ...
... WASHINGTON, Dec. 12 Speaker Nancy Pelosi,Majority Leader Steny ... Rahm Emanuel held a news conference late this afternoon ... news conference, President,Bush vetoed the bill. Below are the ... that later today that the President,will veto the SCHIP ...
... experts say recall shouldn,t be health threat , , WEDNESDAY, ... 1.2 million doses of a common childhood vaccine due ... vaccine does not pose a health threat, U.S. health ... recalled two lots of the Haemophilus influenzae ...
... A new school curriculum,that counters abuse of prescription ... a press conference today in Washington, D.C. The,curriculum ... as presentations,for parents. This curriculum was created by ... and expertise of law enforcement,officials; the Pharmaceutical Research ...
Cached Medicine News:Health News:BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 2Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Common Infant Vaccine Recalled 2Health News:Common Infant Vaccine Recalled 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 2Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: